CN116211974B - 一种改善人体微循环的中药组合物 - Google Patents
一种改善人体微循环的中药组合物 Download PDFInfo
- Publication number
- CN116211974B CN116211974B CN202211573277.4A CN202211573277A CN116211974B CN 116211974 B CN116211974 B CN 116211974B CN 202211573277 A CN202211573277 A CN 202211573277A CN 116211974 B CN116211974 B CN 116211974B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 108
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 230000004089 microcirculation Effects 0.000 title abstract description 36
- 210000004369 blood Anatomy 0.000 claims abstract description 71
- 239000008280 blood Substances 0.000 claims abstract description 71
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 31
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 16
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 16
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 16
- 241000405414 Rehmannia Species 0.000 claims abstract description 16
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 15
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 15
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 15
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 15
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 15
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 15
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 15
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 15
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 15
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 15
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 15
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 15
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 15
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 15
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 15
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 15
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 15
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 15
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 15
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 15
- 240000000249 Morus alba Species 0.000 claims abstract description 15
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 15
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 15
- 244000197580 Poria cocos Species 0.000 claims abstract description 15
- 241000220317 Rosa Species 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 14
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 7
- 244000194101 Ginkgo biloba Species 0.000 claims abstract 3
- 239000007788 liquid Substances 0.000 claims description 26
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 claims description 14
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 claims description 14
- 244000046146 Pueraria lobata Species 0.000 claims description 9
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 9
- 241000212322 Levisticum officinale Species 0.000 claims description 8
- 241000756042 Polygonatum Species 0.000 claims description 8
- 235000008737 Polygonatum biflorum Nutrition 0.000 claims description 8
- 239000001645 levisticum officinale Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 241001633680 Polygonatum odoratum Species 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 4
- 241000628997 Flos Species 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 210000000952 spleen Anatomy 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 17
- 235000009508 confectionery Nutrition 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 14
- 241000218628 Ginkgo Species 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 239000002994 raw material Substances 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 206010011224 Cough Diseases 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000004998 Abdominal Pain Diseases 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 206010033557 Palpitations Diseases 0.000 description 6
- 235000021152 breakfast Nutrition 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 229960004580 glibenclamide Drugs 0.000 description 6
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 6
- 230000000291 postprandial effect Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 201000009240 nasopharyngitis Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 208000034507 Haematemesis Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008081 blood perfusion Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000002960 lipid emulsion Substances 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 206010060710 Galactostasis Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000024241 parasitism Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 241000123846 Buddleja officinalis Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241001278833 Rosa laevigata Species 0.000 description 1
- 235000000661 Rosa laevigata Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940038481 bee pollen Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种改善人体微循环的中药组合物,涉及中药制品技术领域。本发明所述中药组合物由川芎、三七、当归、麦芽、茯苓、甘草、黄精、山药、银杏叶、龙眼肉、玫瑰花、熟地黄、山楂、人参、葛根、桑叶、玉竹、栀子、槐米共十九味中药组成。本发明中药组合物不仅能打通人体微循环,降脂降压,改善人体亚健康状态,使机体各器官恢复平衡状态,而且本发明中药组合物由纯中药制成无任何毒副作用。
Description
技术领域
本发明涉及中药制品技术领域,具体涉及一种改善人体微循环的中药组合物。
背景技术
微循环是人体新陈代谢的场所,是人体的内环境,是生命最基本的保证。微循环包括微动脉、毛细血管、动-静脉吻合枝、微静脉,以及毛细淋巴管和组织内的体液循环,相当于中医学上的“经络”范畴。微循环的主要功能是给组织细胞供应氧气和养料,带走细胞产生的二氧化碳和乳酸等代谢产物。如果微循环发生障碍,血液灌注量就会减少,难以满足组织氧化代谢的需要,轻则造成机能功能退化,严重时就会导致机体许多疾病的发生,包括高血压、高血脂、糖尿病、肿瘤等多种慢性病。改善微循环有助于身体的强健和疾病的康复,寻求好的改善微循环的方法一直为医学界所重视。
中医上讲通则不痛,痛则不通,改善人体的微循环,可以从根本上治疗和预防疾病的发生。现有技术中的中药多数都是针对一种疾病的治疗,起不到改善人体微循环的作用,发挥不了中医中药的优势。研究一种能够改善人体微循环的中药组合物,不仅是临床需要,对于人类身体的强健和健康长寿都具有重大意义。
发明内容
(一)解决的技术问题
针对现有技术的不足,本发明提供了一种改善人体微循环和降低血脂的中药组合物,所述中药组合物能够打通人体微循环,有利于降血脂和降血压,改善人体亚健康状态,使机体各器官恢复平衡状态。
(二)技术方案
为实现以上目的,本发明通过以下技术方案予以实现:
一方面,本发明提供一种改善人体微循环和降低血脂的中药组合物,所述中药组合物由以下重量份数的中药组分组成:川芎30-90份、三七20-50份、当归20-50份、麦芽30-50份、茯苓10-40份、甘草10-20份、黄精20-40份、山药20-40份、银杏叶20-40份、龙眼肉10-30份、玫瑰花10-20份、熟地黄10-20份、山楂10-30份、人参叶10-20份、葛根20-40份、桑叶10-20份、玉竹20-40份、栀子10-20份、槐米10-20份。
进一步地,作为一种改善人体微循环和降低血脂的中药组合物的优化,所述中药组合物由以下重量份数的中药组分组成:川芎40-80份、三七20-40份、当归20-40份、麦芽30-40份、茯苓15-30份、甘草12-18份、黄精25-35份、山药25-35份、银杏叶25-35份、龙眼肉10-20份、玫瑰花12-18份、熟地黄12-18份、山楂15-25份、人参叶12-18份、葛根25-35份、桑叶12-18份、玉竹25-35份、栀子12-18份、槐米12-18份。
进一步地,作为一种改善人体微循环和降低血脂的中药组合物的优化,所述中药组合物由以下重量份数的中药组分组成:川芎60份、三七30份、当归25份、麦芽35份、茯苓20份、甘草15份、黄精30份、山药30份、银杏叶30份、龙眼肉15份、玫瑰花15份、熟地黄15份、山楂20份、人参叶15份、葛根30份、桑叶15份、玉竹30份、栀子15份、槐米15份。
另一方面,本发明还提供了一种改善人体微循环和降低血脂的中药组合物的应用,所述中药组合物是用于制备改善人体微循环和降低血脂的药物;所述中药组合物按常规的中药制备方法制成适用于药用的口服液。
本发明中药组合物中各中药原料的药理作用:
川芎:辛,温;归肝,胆经;行气开郁,祛除风燥湿,活血止痛;用于风冷头痛旋晕,胁痛腹疼,寒痹筋挛,经闭,难产,产后瘀阻块痛,痈疽疮疡,月经不调,经闭痛经,瘕腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。
三七:甘,微苦,温;归肝,胃经;散瘀止血,消肿定痛;用于咯血,吐血,衄血,便血,崩漏,外伤出血,胸腹刺痛,跌扑肿痛。
当归:甘,辛,温;归肝,心,脾经;补血,活血,调经止痛,润燥滑肠;用于月经不调,经闭,痛经,症瘕结聚,崩漏,虚寒腹痛,痿痹,肌肤麻木,肠燥便难,赤痢后重,痈疽疮疡,跌扑损伤。
麦芽:甘,平;归脾,胃经;行气消食,健脾开胃,回乳消胀;用于食积不消,脘腹胀痛,脾虚食少,乳汁郁积,乳房胀痛,妇女断乳,肝郁胁痛,肝胃气痛。
茯苓:甘,淡,性平;归心,肺,脾,肾经;利水渗湿,健脾,宁心;用于水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠。
甘草:甘,平;归心,肺,脾,胃经;补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药;用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
黄精:甘,平;归肺,脾,肾经;补气养阴,健脾,润肺,益肾;用于脾胃虚弱,体倦乏力,口干食少,肺虚燥咳,精血不足,内热消渴。
山药:甘,平;归手,足太阴二经;健脾,补肺,固肾,益精;用于脾虚泄泻,久痢,虚劳咳嗽,消渴,遗精,带下,小便频数。
银杏叶:甘,苦,涩,平;归心,肺经;活血化瘀,通络止痛,敛肺平喘,化浊降脂;用于瘀血阻络,胸痹心痛,中风偏瘫,肺虚咳喘,高脂血症。
龙眼肉:甘,温;归心,脾经;补益心脾,养血安神;用于气血不足,心悸怔忡,健忘失眠,血虚萎黄。
玫瑰花:甘,微苦,温;归肝,脾二经;行气解郁,和血散瘀;用于肝胃气痛,新久风痹,吐血咯血,月经不调,赤白带下,痢疾,乳痈,肿毒。
熟地黄:苦,温;归心,肝,肾经;补血滋阴,益精填髓;用于血虚萎黄,心悸怔忡,月经不调,崩漏下血,肝肾阴虚,腰膝酸软,骨蒸潮热,盗汗遗精,内热消渴,眩晕,耳鸣,须发早白。
山楂:酸,甘,微温;归脾,肝二经;消食健胃,行气散瘀,化浊降脂;用于肉食积滞,胃脘胀满,泻痢腹痛,瘀血经闭,产后瘀阻,心腹刺痛,胸痹心痛,疝气疼痛,高脂血症。
人参叶:苦,微甘,寒;归肺,胃二经;补气,益肺,祛暑,生津;用于气虚咳嗽,暑热烦躁,津伤口渴,头目不清,四肢倦乏。
葛根:味甘、辛,性凉;归肺、胃经;有解肌退热、透疹、生津止渴、升阳止泻之功效;用于表证发热、麻疹不透、阴虚消渴、脾虚泄泻等症。
桑叶:味苦、甘,性寒;归肺、肝经;有疏散风热、清肺润燥、平肝明目、凉血止血之功效;用于风热感冒、温病初起、肺热咳嗽、目赤昏花等症。
玉竹:味甘,性寒;入肺、胃经;养阴润燥、生津止渴;用于热病伤阴、烦热口渴、咽干、肺热干咳等症。
栀子:味苦,性寒;归心、肺、三焦经;泻火除烦、清热利湿、凉血解毒;用于热病心烦、湿热黄疸、淋证涩痛、目赤肿痛等症。
槐米:凉血止血,清肝泻火;用于便血、痔血、血痢、崩漏、吐血、衄血、肝热目赤、头痛眩晕。
(三)有益效果
本发明提供了一种改善人体微循环的中药组合物,本发明以纯天然植物为原料,根据中医经络循环理论,运用中医“君臣佐使”原理合理配伍,选用川芎、三七、当归、麦芽、茯苓、甘草、黄精、山药、银杏叶、龙眼肉、玫瑰花、熟地黄、山楂、人参、葛根、桑叶、玉竹、栀子、槐米共十九味中药组成。本发明中药组合物不仅能打通人体微循环,还有利于降血脂、降血压和降血糖,改善人体亚健康状态,使机体各器官恢复平衡状态,而且本发明中药组合物由纯中药制成,服用后无毒副作用。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种改善人体微循环和降低血脂的中药组合物,按照下述份数称取各原料:川芎60份、三七30份、当归25份、麦芽35份、茯苓20份、甘草15份、黄精30份、山药30份、银杏叶30份、龙眼肉15份、玫瑰花15份、熟地黄15份、山楂20份、人参叶15份、葛根30份、桑叶15份、玉竹30份、栀子15份、槐米15份。
实施例2
一种改善人体微循环和降低血脂的中药组合物,按照下述份数称取各原料:川芎30份、三七20份、当归20份、麦芽35份、茯苓10份、甘草15份、黄精20份、山药20份、银杏叶20份、龙眼肉10份、玫瑰花10份、熟地黄10份、山楂10份、人参叶10份、葛根20份、桑叶10份、玉竹20份、栀子10份、槐米10份。
实施例3
一种改善人体微循环和降低血脂的中药组合物,按照下述份数称取各原料:川芎90份、三七50份、当归50份、麦芽50份、茯苓40份、甘草20份、黄精40份、山药35份、银杏叶40份、龙眼肉30份、玫瑰花20份、熟地黄20份、山楂25份、人参叶20份、葛根40份、桑叶20份、玉竹40份、栀子20份、槐米20份。
实施例4
一种改善人体微循环和降低血脂的中药组合物,按照下述份数称取各原料:川芎50份、三七40份、当归40份、麦芽35份、茯苓30份、甘草15份、黄精30份、山药25份、银杏叶25份、龙眼肉15份、玫瑰花13份、熟地黄13份、山楂25份、人参叶13份、葛根25份、桑叶13份、玉竹25份、栀子13份、槐米13份。
实施例5
一种改善人体微循环和降低血脂的中药组合物,按照下述份数称取各原料:川芎40份、三七40份、当归30份、麦芽40份、茯苓25份、甘草18份、黄精25份、山药35份、银杏叶35份、龙眼肉20份、玫瑰花15份、熟地黄15份、山楂20份、人参叶15份、葛根35份、桑叶15份、玉竹35份、栀子15份、槐米15份。
实施例6
一种改善人体微循环和降低血脂的中药组合物,按照下述份数称取各原料:川芎65份、三七35份、当归35份、麦芽45份、茯苓30份、甘草15份、黄精30份、山药30份、银杏叶30份、龙眼肉25份、玫瑰花20份、熟地黄20份、山楂10份、人参叶15份、葛根30份、桑叶15份、玉竹30份、栀子15份、槐米15份。
实施例7
一种改善人体微循环和降低血脂的中药组合物,按照下述份数称取各原料:川芎45份、三七25份、当归25份、麦芽35份、茯苓20份、甘草15份、黄精25份、山药25份、银杏叶25份、龙眼肉10份、玫瑰花15份、熟地黄10份、山楂20份、人参叶10份、葛根25份、桑叶10份、玉竹25份、栀子10份、槐米10份。
试验例1
1材料与方法
1.1试验材料
1.1.1各组中药组合物的原料组分
本发明中药组合物按照实施例1所述重量份数的中药组分制备;中药1组为公开号为CN113616708A的专利所描述的一种打通微循环的中药组合物1,该中药组合物由以下重量的中药组分组成:密蒙花45g,夜明砂45g,菊花45g,枸杞45g,白术30g,鸡内金30g,丹参30g,川穹30g;中药2组为公开号为CN104324134A的专利所描述的一种改善微循环的中药组合物2,该中药组合物由以下重量份数的中药组分组成:黑血藤35份、蜂花粉45份、丹参20份、赤芍15份、三七4份、太子参4份、熟地5份、龙眼树寄生4份、金樱子寄生4份;本发明中药组合物、中药组合物1、中药组合物2均按常规的中药制备方法制成适用于药用的口服药物,浓度为0.2g/ml(每毫升口服液相当于原生药材0.2g)。
1.1.2高脂血症小鼠模型的构建
50只SPF级雄性健康ICR小鼠购买自扬州大学,实验动物使用许可证:SYXK(苏)2022-0044,体重为24±2g,适应性饲养7天。分为空白组10只和建模组40只。按常规方法制备脂乳剂,对建模组小鼠灌胃脂乳剂3周构建高脂血症小鼠模型,空白组小鼠不做处理。所有小鼠均正常饮水,自由进食普通饲料。
1.1.3动物分组
灌胃脂乳剂3周后,40只建模组小鼠随机平均分为模型组、中药1组、中药2组、本发明配方组,每组10只。模型组小鼠灌胃生理盐水,剂量为0.2mL/只;中药1组小鼠灌胃中药组合物1所制得的口服液,剂量为0.2mL/只;中药2组小鼠灌胃中药组合物2所制得的中药组合物口服液,剂量为0.2mL/只;本发明配方组灌胃本发明中药组合物口服液,剂量为0.2mL/只。空白组小鼠不做处理。连续给药21天,每天给药1次,给药期间所有小鼠均正常饮水,自由进食普通饲料。
1.2血液指标检测
末次给药2h后,对小鼠腹腔注射戊巴比妥钠麻醉后,自眼底静脉丛取血,离心分离血清,采用全自动生化仪检测甘油三酯(TG)、胆固醇(CHO)、低密度脂蛋白(LDL-C)指标。
1.3统计学分析
数据分析采用SPSS.17软件对所有数据进行统计性检验,结果用平均数±标准差表示,以(P<0.05)表示差异显著。
2结果
给药21天后,各组小鼠血液指标检测结果见表1。与空白组相比,模型组小鼠血清中TG、CHO、LDL-C含量显著升高,表明脂乳剂诱导的小鼠高脂血症模型造模成功。与模型组小鼠相比,中药1组、中药2组、本发明配方组小鼠血清中TG、CHO、LDL-C含量均有不同程度下降。其中,中药2组小鼠血清中CHO含量与模型组相比显著下降;本发明配方组小鼠血清中CHO、LDL-C含量与模型组相比显著下降。对比中药1组、中药2组、本发明配方组,可见本发明配方组中TG、CHO、LDL-C的含量均为3组中最低,说明本发明配方组在降低血脂方面的作用优于中药1组和中药2组。
表1各组小鼠血液指标检测结果
组别 | 样本数 | TG(mmol/L) | CHO(mmol/L) | LDL-C(mmol/L) |
空白组 | 10 | 1.09±0.28 | 2.92±0.48 | 0.41±0.20 |
模型组 | 10 | 2.01±0.45* | 3.42±0.46* | 0.63±0.18* |
中药1组 | 10 | 1.91±0.52 | 3.15±0.59 | 0.58±0.23 |
中药2组 | 10 | 1.94±0.41 | 2.78±0.42# | 0.54±0.25 |
本发明配方组 | 10 | 1.79±0.58 | 2.69±0.39# | 0.45±0.14# |
注:模型组与空白组对比,*P<0.05;中药1组、中药2组、本发明配方组与模型组对比,#P<0.05。
试验例2
为进一步验证本发明中药组合物在改善人体微循环上的有效性,现提供以下II型糖尿病临床试验进行说明。
1研究对象
凡符合西医II型糖尿病诊断标准和中医证候诊断标准患者,且愿意接受3个月疗程治疗者,纳入本研究。本试验共纳入II型糖尿病患者64例,其中西药治疗组和西药联合本发明中药组合物治疗组各32例,两组患者在性别、年龄、病程、病情方面均无显著性差异(P>0.05)。
2治疗方式
西药治疗组患者口服格列本脲片,剂量为2.5mg/次,每日早晚餐前半小时服用,每日共服用2次。
西药联合本发明中药组合物治疗组患者同时服用格列本脲片和本发明中药口服液,格列本脲片的用药剂量为2.5mg/次,本发明中药口服液的用药剂量为10ml/次(浓度为1.5g/ml),两种药物均每日早晚餐前半小时服用,每日共服用2次。
3检测指标
两组患者均持续用药3个月,3个月后检测患者血糖改善情况及脂代谢水平的变化,检测指标包括空腹血糖、餐后1h血糖、餐后2h血糖、血清CHO、血清TG、血尿酸。
4统计学分析
数据分析采用SPSS软件对所有数据进行统计性检验,结果用平均数±标准差表示,以(P<0.05)表示差异显著。
5结果
5.1血糖指标改善情况
由表2可知,两组患者在治疗3个月后,空腹血糖、餐后1h血糖、餐后2h血糖指标均有显著下降。联合服用格列本脲片及本发明中药口服液的患者空腹血糖、餐后1h血糖、餐后2h血糖指标与单独的西药治疗组相比略有下降,但差异不显著。
表2两组患者血糖指标表
注:与各组治疗前比较,*P<0.05。
5.2脂代谢指标改善情况
治疗3个月后,检测两组患者的脂代谢指标,由表3可知,西药治疗组患者治疗前后血清CHO、血清TG、血尿酸水平无显著变化。西药联合本发明中药口服液治疗可显著降低II型糖尿病患者血清CHO、血清TG、血尿酸水平,说明本发明中药口服液改善脂代谢效果显著。
表3两组患者脂代谢指标表
注:与各组治疗前比较,*P<0.05。
试验例3
为进一步验证本发明中药组合物在改善人体微循环上的有效性,现提供5例临床典型病例进行说明,所服用中药口服液是根据实施例1所述组方按照常规方法制备得到的口服液,药物浓度为1.5g/mL。
王某,男,62岁,身体虚弱,经常感冒,睡眠不好,血压高,一直服用硝苯地平治疗高血压。自2020年8月开始联合服用本发明中药口服液,用药剂量为10ml/次,每日早晚餐前半小时服用,每日服用2次,联合服药一年半后,自述感冒明显减少,特别是近一年未得过感冒,睡眠质量提高,在停用降压药硝苯地平后,血压仍能维持在130/75左右。
韦某某,女,79岁,头晕,心悸,胸闷,尿频,手脚怕冷,饭后易腹胀,经诊断为高脂血症,一直服用洛伐他汀降低血脂。患者联合服用本发明中药口服液6个月,用药剂量为10ml/次,每日早晚餐前半小时服用,每日服用2次,自述精神状态恢复,上述症状均有减轻。
田某某,男,52岁,患帕金森1年,患病1年来精神萎靡,手足抖动越来越重,自确诊后一直服用左旋多巴治疗。联合服用本发明中药口服液6个月,用药剂量为10ml/次,每日早晚餐前半小时服用,每日服用2次,自觉手足抖动症状减轻,联合服用1年后,患者自述手足抖动症状得到明显减轻,精神状况得到明显改善。
燕某,女,64岁,多饮多食多尿并伴有体重减轻,睡眠质量不佳,经诊断为II型糖尿病,服用西药吡格列酮治疗,用药剂量为10ml/次,每日服用2次。联合服用本发明中药口服液6个月后,患者自述睡眠质量明显改善,情绪好转。
王某某,女,68岁,身体容易感觉冷,同期穿衣比别人多,易疲乏。2021年9月开始服用本发明中药口服液治疗,用药剂量为10ml/次,每日早晚餐前半小时服用,每日服用2次,服药9个月后随访,自述身体不经常感觉冷了,疲惫感减轻,精神明显好转。
综上,本发明实施例具有如下有益效果:
本发明中药组合物能够有效改善机体微循环,疏通机体经络,且具有良好的降脂、降血压和降血糖作用,改善人体亚健康状态,使机体各器官恢复平衡状态,对多种微循环相关的慢性病有较好的疗效。
以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (4)
1.一种降血脂、降血糖的中药组合物,其特征在于,所述中药组合物由以下重量份数的中药组分组成:川芎40-80份、三七20-40份、当归20-40份、麦芽30-40份、茯苓15-30份、甘草12-18份、黄精25-35份、山药25-35份、银杏叶25-35份、龙眼肉10-20份、玫瑰花12-18份、熟地黄12-18份、山楂15-25份、人参叶12-18份、葛根25-35份、桑叶12-18份、玉竹25-35份、栀子12-18份、槐米12-18份。
2.根据权利要求1所述的一种降血脂、降血糖的中药组合物,其特征在于,所述中药组合物由以下重量份数的中药组分组成:川芎60份、三七30份、当归25份、麦芽35份、茯苓20份、甘草15份、黄精30份、山药30份、银杏叶30份、龙眼肉15份、玫瑰花15份、熟地黄15份、山楂20份、人参叶15份、葛根30份、桑叶15份、玉竹30份、栀子15份、槐米15份。
3.如权利要求1所述的一种降血脂、降血糖的中药组合物,其特征在于,所述中药组合物按照药剂学中常规的制药方法,配以医学上可接受的辅料,制成颗粒剂、散剂、口服液、片剂或其他药剂学上可接受的口服剂型。
4.如权利要求1所述的一种降血脂、降血糖的中药组合物,其特征在于,所述中药组合物是用于降血脂、降血糖的药物的制备。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211573277.4A CN116211974B (zh) | 2022-12-08 | 2022-12-08 | 一种改善人体微循环的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211573277.4A CN116211974B (zh) | 2022-12-08 | 2022-12-08 | 一种改善人体微循环的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116211974A CN116211974A (zh) | 2023-06-06 |
CN116211974B true CN116211974B (zh) | 2024-02-23 |
Family
ID=86589973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211573277.4A Active CN116211974B (zh) | 2022-12-08 | 2022-12-08 | 一种改善人体微循环的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116211974B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101524421A (zh) * | 2008-12-31 | 2009-09-09 | 江西本草天工科技有限责任公司 | 一种治疗心脑血管疾病的中药制剂 |
CN101904492A (zh) * | 2010-03-25 | 2010-12-08 | 马宏达 | 调节血糖促进脏腑平衡的功能食品制备方法 |
CN109055141A (zh) * | 2018-10-08 | 2018-12-21 | 浙江中医药大学 | 一种黑莓黄酒及其制备方法和应用 |
CN110384777A (zh) * | 2019-08-09 | 2019-10-29 | 武余顺 | 一种糖尿病化糖的配方食品 |
-
2022
- 2022-12-08 CN CN202211573277.4A patent/CN116211974B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101524421A (zh) * | 2008-12-31 | 2009-09-09 | 江西本草天工科技有限责任公司 | 一种治疗心脑血管疾病的中药制剂 |
CN101904492A (zh) * | 2010-03-25 | 2010-12-08 | 马宏达 | 调节血糖促进脏腑平衡的功能食品制备方法 |
CN109055141A (zh) * | 2018-10-08 | 2018-12-21 | 浙江中医药大学 | 一种黑莓黄酒及其制备方法和应用 |
CN110384777A (zh) * | 2019-08-09 | 2019-10-29 | 武余顺 | 一种糖尿病化糖的配方食品 |
Non-Patent Citations (1)
Title |
---|
阿托伐他汀联合化瘀调脂汤对脑梗死合并颈动脉粥样硬化斑块患者血脂及血流变的影响;周峻 等;中国乡村医药;-;第21卷(第14期);第26-27、33页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116211974A (zh) | 2023-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102698097B (zh) | 用于治疗牙周炎的中药组合物、其剂型、制备方法和牙膏 | |
CN111729064A (zh) | 一种健脾通阳中药组合物及其应用 | |
CN103638451A (zh) | 一种治疗慢性肝炎的中药及其制备方法 | |
CN104815318A (zh) | 一种治疗痛风的中药制剂 | |
CN111249420A (zh) | 一种调治气郁体质的中药组合物及其制剂和应用 | |
CN103341092A (zh) | 一种治疗萎缩性阴道炎的散剂制备方法 | |
CN102579975B (zh) | 一种治疗银屑病的中药混合物 | |
CN116211974B (zh) | 一种改善人体微循环的中药组合物 | |
CN103920058A (zh) | 一种治疗头痛的中药制剂及其制备方法 | |
CN103028047A (zh) | 一种治疗慢性咽喉炎的中成药 | |
CN102579895B (zh) | 一种治疗银屑病的中药组合物 | |
CN105833055A (zh) | 一种治疗“三高”的中药组合物、其制备方法和应用 | |
CN104998158A (zh) | 一种治疗肝硬化的药物组合物及其应用 | |
CN104887950A (zh) | 一种治疗乳痈的中药组合物 | |
CN104840902A (zh) | 一种治疗卵巢肿瘤的中药制剂 | |
CN103301373A (zh) | 一种治疗产后会阴粘膜病变的药物组合物 | |
CN108853340A (zh) | 一种滋养肝肾的中药及其制备方法 | |
CN102552824B (zh) | 用于治疗银屑病的中成药 | |
CN102416099A (zh) | 一种治疗银屑病的中药 | |
CN105770520A (zh) | 一种用于治疗冠心病的药物制剂及其用途 | |
CN105106884B (zh) | 益气活血泄浊方 | |
CN105213975A (zh) | 一种治疗肝硬化的药物组合物及其应用 | |
CN104758889A (zh) | 一种治疗糖尿病的中药组合物 | |
CN117599125A (zh) | 一种用于治疗骨质疏松症的补钙壮骨中药组合物及制法和应用 | |
CN103316270A (zh) | 一种治疗产后会阴粘膜病变药物的散剂制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |